Thursday , July 20 2017
Home / Rheumatoid Arthritis

Rheumatoid Arthritis

Pfizer Announces Results from Xeljanz ORAL Strategy Study in Patients with Rheumatoid Arthritis

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today detailed results from ORAL Strategy, a head-to-head, noninferiority Phase 3b/4 study of XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) as monotherapy or in combination with methotrexate (MTX) compared to Humira® plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). …

Read More »

Janssen Presents Long Term Phase 3 Safety and Efficacy Data of Sirukumab in Difficult-to-Treat RA Patients

Janssen-Cilag International NV (Janssen) today announced long-term results from SIRROUND-T*, a pivotal Phase 3 study that showed sirukumab improved the signs and symptoms of moderately to severely active rheumatoid arthritis (RA) through 52 weeks of treatment in adult patients with an inadequate response and/or intolerance to anti-tumor necrosis factor (TNF)-alpha …

Read More »

Johnson & Johnson Innovation Announces New Collaborations Advancing Ground-Breaking Biomedical Innovation

NEW BRUNSWICK, N.J., June 15, 2017 /PRNewswire/ — Johnson & Johnson Innovation LLC today announced new collaborations that seek to develop potential treatments for diseases in urgent need of solutions, including obesity and related complications, such as type 2 diabetes and non-alcoholic steatohepatitis (NASH), and rheumatoid arthritis, and advance cutting-edge …

Read More »

Results from Late-Stage Study Demonstrate Clinical Equivalence of Boehringer Ingelheim’s Adalimumab Biosimilar Candidate to Humira

Ingelheim/Germany and Madrid/Spain, June 14, 2017 – Boehringer Ingelheim announced today results from the pivotal Phase III VOLTAIRE®-RA1  study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis. The 24 week results will be presented at …

Read More »

AbbVie’s Upadacitinib Meets All Primary and Ranked Secondary Endpoints in Late-Stage Rheumatoid Arthritis Study

NORTH CHICAGO, Ill., June 7, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-NEXT clinical trial evaluating upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis (RA) who did not adequately respond to …

Read More »

Regeneron and Sanofi Announce FDA Approval of Kevzara for Treatment of Rheumatoid Arthritis

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), …

Read More »

Eighty Percent of RA Patients Report Life-Altering Pain Daily or Multiple Times a Week Despite Treatment, According to Survey Results

BRIDGEWATER, N.J. and TARRYTOWN, N.Y., May 2, 2017 /PRNewswire/ — Honestly RA, a new survey of more than 1,000 people in the United States living with rheumatoid arthritis (RA), found that even after treatment, approximately 80 percent of RA patients experience pain daily or multiple times per week.1 Conducted by …

Read More »

Samsung Bioepis’ Biosimilar Version of Remicade Receives FDA Approval

INCHEON, Korea – April 24, 2017 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved RENFLEXIS™ (infliximab-abda), a biosimilar referencing Remicade®i (infliximab), across all eligible indications. In the US, RENFLEXIS™ is indicated for reducing signs and symptoms in patients with adult and …

Read More »

FDA Approves Silvergate’s XATMEP, the Only Ready-to-Use Methotrexate Oral Solution

DENVER, April 26, 2017 /PRNewswire/ — Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leaders in the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved XATMEP (methotrexate) Oral Solution, the first and only FDA-approved methotrexate oral solution. XATMEP is indicated …

Read More »

Lilly and Incyte Announce FDA Fails to Approve Baricitinib for Rheumatoid Arthritis

INDIANAPOLIS–(BUSINESS WIRE)–Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA). The …

Read More »